Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib versus sunitinib in MET-driven papillary renal cell carcinoma
2016-004108-73Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in papillary renal cell carcinoma (PRCC) and kidney cancer comparing Savolitinib with Sunitinib (2 arms). Primary endpoint: Progression-free survival. Started Jan 2018; status: completed.
02
Drugs
savolitinibsunitinib
03
Conditions
papillary renal cell carcinoma (PRCC)kidney cancer
Beyond the preview
Go deeper on 2016-004108-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004108-73.